This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

An Efficacy and Tolerability Study for Topiramate in Obese Patients With Binge Eating Disorder.

This study has been completed.
Information provided by:
Janssen-Cilag Farmaceutica Ltda. Identifier:
First received: March 24, 2006
Last updated: January 27, 2011
Last verified: January 2011
The purpose of this study is to evaluate the effectiveness and tolerability of topiramate compared to placebo in patients with binge eating disorder receiving Cognitive Behavior Therapy (CBT)

Condition Intervention Phase
Binge Eating Drug: topiramate Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Randomized, Double-blind Placebo Controlled Trial With Topiramate for the Treatment of Obese Patients With Binge Eating Disorder

Resource links provided by NLM:

Further study details as provided by Janssen-Cilag Farmaceutica Ltda.:

Primary Outcome Measures:
  • Weight, Body Mass Index,number of binge eating and anthropometric measurements

Secondary Outcome Measures:
  • changes in blood pressure, serum triglycerides levels, serum cholesterol levels, beck depression scale scores.

Enrollment: 73
Study Start Date: November 2003
Study Completion Date: April 2005
Detailed Description:
This was a 21-week multicenter, double-blind, parallel-group, randomized controlled trial comparing the efficacy and tolerability of an add-on treatment with 200mg of topiramate versus placebo in obese patients with BED receiving group CBT. The aim of this trial is to investigate the efficacy and tolerability of adjunctive topiramate to CBT in obese patients with BED through improvement in binge eating, related psychopathology, and weight loss. The study hypothesis is that the patients using topiramate + CBT will loose more weight than patients using placebo + CBT.Tolerability will be investigated through reported adverse events and dropouts, with reasons for leaving the study being analyzed. The randomized patients will receive capsules of topiramate (25 mg, 50 mg) or placebo correspondent daily for 21 weeks

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Have been meeting the diagnostic criteria for binge eating disorder (according to the Diagnostic and Statistical Manual for Mental Disorders - IV Edition criteria) with at least 2 days of binge eating per week and severity at least moderate defined by binge eating scale (score = 17)
  • BMI = > 30 kg/m2 to < 46 kg/m2
  • Women must be post menopausal for at least one year or surgically sterilized (hysterectomy, tubal ligation), or practice sexual abstinence or use an acceptable method of birth control (i.e. a hormonal contraceptive, spermicide plus barrier method, intrauterine device and/or vasectomized partner)

Exclusion Criteria:

  • Has a history or actual diagnostic of significant psychiatric disorder (schizophrenia, psychosis, major affective disorder, suicide risk, dementia, abuses alcohol or other drugs)
  • has a malignancy or a history of malignancy within the past 5 years (except basal cell carcinoma)
  • evidence of uncontrolled thyroid disorders
  • uncontrolled hypertension (defined as a diastolic blood pressure >110 mm/Hg and/or a systolic blood pressure >180 mm/Hg with or without medication). Hypertensive patients on medications must have been on the same dose of the same antihypertensive medication for at least two months
  • history or significant renal failure or glaucoma.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00307619

Sponsors and Collaborators
Janssen-Cilag Farmaceutica Ltda.
Study Director: Janssen-Cilag Farmaceutica Ltda. Clinical Trial Janssen-Cilag Farmaceutica Ltda.
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00307619     History of Changes
Other Study ID Numbers: CR003667
Study First Received: March 24, 2006
Last Updated: January 27, 2011

Keywords provided by Janssen-Cilag Farmaceutica Ltda.:
Binge-Eating Disorder

Additional relevant MeSH terms:
Feeding and Eating Disorders
Binge-Eating Disorder
Mental Disorders
Signs and Symptoms, Digestive
Signs and Symptoms
Neuroprotective Agents
Protective Agents
Physiological Effects of Drugs
Anti-Obesity Agents processed this record on September 25, 2017